BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9531053)

  • 1. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
    Wittig K; Rothe G; Schmitz G
    Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].
    Khaspekova SG; Vyzova TV; Lukin VV; Tikhomirov OIu; Berndt M; Kouns W; Mazurov AV
    Biokhimiia; 1996 Mar; 61(3):412-28. PubMed ID: 8724599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
    Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
    Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
    Xiao Z; Théroux P; Frojmovic M
    Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY; Wu YC; Wu CC
    Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
    Tsikaris V
    J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of disagregin with the platelet fibrinogen receptor, glycoprotein IIb-IIIa.
    Karczewski J; Connolly TM
    Biochem Biophys Res Commun; 1997 Dec; 241(3):744-8. PubMed ID: 9434779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of human platelet IgG Fc receptor associated with membrane glycoprotein.
    Shido K; Ahmad G; Hsu L; Kamiyama M
    J Clin Lab Immunol; 1995; 46(1):1-11. PubMed ID: 9363587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-binding assays: fibrinogen.
    Cox D
    Methods Mol Biol; 2004; 273():125-38. PubMed ID: 15308798
    [No Abstract]   [Full Text] [Related]  

  • 12. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
    Zhao L; Bath PM; May J; Lösche W; Heptinstall S
    Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aged garlic extract inhibits platelet activation by increasing intracellular cAMP and reducing the interaction of GPIIb/IIIa receptor with fibrinogen.
    Allison GL; Lowe GM; Rahman K
    Life Sci; 2012 Dec; 91(25-26):1275-80. PubMed ID: 23069586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the role of adjacent amino acids to the 313-320 sequence of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.
    Mitsios JV; Stamos G; Rodis FI; Tsironis LD; Stanica MR; Sakarellos C; Tsoukatos D; Tsikaris V; Tselepis AD
    Platelets; 2006 Aug; 17(5):277-82. PubMed ID: 16928597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
    Manaster Y; Shenkman B; Rosenberg N; Savion N
    Thromb Res; 2009 Sep; 124(4):477-82. PubMed ID: 19632706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets.
    Peerschke EI
    Thromb Haemost; 1995 May; 73(5):862-7. PubMed ID: 7482417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.
    Barre DE
    Thromb Res; 2007; 119(5):601-7. PubMed ID: 16860375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
    Huang TF; Chang CH; Ho PL; Chung CH
    Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
    Klinkhardt U; Kirchmaier CM; Westrup D; Breddin HK; Mahnel R; Graff J; Hild M; Harder S
    Thromb Res; 2000 Feb; 97(4):201-7. PubMed ID: 10674406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.